Payment overview · 2025
General Payments
$243.53
14 reported records · 9 companies
Healthcare provider profile · identity verified
John R Herring
Allopathic & Osteopathic Physicians|Family Medicine · GREERS FERRY, AR · NPI 1295747566
Verified facts
What the public records show
CMS Open Payments records show John R Herring received $243.53 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.44 | 31.8% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.09 | 14.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.51 | 12.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.62 | 7.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.11 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.30 | 7.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $15.70 | 6.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.18 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.58 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.53 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.44 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 21 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
147 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1178 | 317 |
| Losartan Potassium | Losartan Potassium | 922 | 255 |
| Levothyroxine Sodium | Levothyroxine Sodium | 881 | 216 |
| Omeprazole | Omeprazole | 720 | 189 |
| Gabapentin | Gabapentin | 629 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 541 | 156 |
| Lisinopril | Lisinopril | 519 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 519 | 134 |
| Hydrochlorothiazide | Hydrochlorothiazide | 450 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 390 | 110 |
| Duloxetine Hcl | Duloxetine Hcl | 380 | 92 |
| Metformin Hcl | Metformin Hcl | 358 | 101 |
| Furosemide | Furosemide | 354 | 106 |
| Trazodone Hcl | Trazodone Hcl | 349 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 310 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 92 |
| Fluticasone Propionate | Fluticasone Propionate | 283 | 84 |
| Sertraline Hcl | Sertraline Hcl | 276 | 69 |
| Glipizide | Glipizide | 266 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 65 |
| Potassium Chloride | Potassium Chloride | 247 | 70 |
| Simvastatin | Simvastatin | 246 | 64 |
| Eliquis | Apixaban | 233 | 50 |
| Montelukast Sodium | Montelukast Sodium | 231 | 60 |
| Ozempic | Semaglutide | 222 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 204 | 49 |
| Famotidine | Famotidine | 200 | 54 |
| Allopurinol | Allopurinol | 195 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 55 |
| Pregabalin | Pregabalin | 177 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 171 | 50 |
| Ezetimibe | Ezetimibe | 169 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 168 | 137 |
| Carvedilol | Carvedilol | 164 | 45 |
| Methylprednisolone | Methylprednisolone | 160 | 140 |
| Topiramate | Topiramate | 159 | 42 |
| Buspirone Hcl | Buspirone Hcl | 155 | 48 |
| Atenolol | Atenolol | 153 | 45 |
| Mounjaro | Tirzepatide | 153 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 37 |
| Meloxicam | Meloxicam | 148 | 46 |
| Alprazolam | Alprazolam | 147 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 147 | 37 |
| Alendronate Sodium | Alendronate Sodium | 144 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 141 | 97 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 41 |
| Azithromycin | Azithromycin | 122 | 104 |
| Estradiol | Estradiol | 121 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 37 |
| Prednisone | Prednisone | 112 | 73 |
| Synthroid | Levothyroxine Sodium | 110 | 27 |
| Tramadol Hcl | Tramadol Hcl | 109 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 108 | 76 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 28 |
| Primidone | Primidone | 94 | 18 |
| Warfarin Sodium | Warfarin Sodium | 93 | 20 |
| Lorazepam | Lorazepam | 92 | 18 |
| Bupropion Xl | Bupropion Hcl | 91 | 20 |
| Propranolol Hcl | Propranolol Hcl | 87 | 23 |
| Trulicity | Dulaglutide | 83 | 17 |
| Finasteride | Finasteride | 81 | 25 |
| Donepezil Hcl | Donepezil Hcl | 79 | 24 |
| Ondansetron Odt | Ondansetron | 79 | 38 |
| Oxybutynin Chloride | Oxybutynin Chloride | 79 | 22 |
| Diazepam | Diazepam | 76 | 19 |
| Celecoxib | Celecoxib | 75 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 12 |
| Temazepam | Temazepam | 74 | 15 |
| Sucralfate | Sucralfate | 73 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Jardiance | Empagliflozin | 69 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 12 |
| Amoxicillin | Amoxicillin | 66 | 58 |
| Mirtazapine | Mirtazapine | 66 | 21 |
| Terbinafine Hcl | Terbinafine Hcl | 66 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 30 |
| Valsartan | Valsartan | 65 | 19 |
| Clonazepam | Clonazepam | 64 | 18 |
| Azelastine Hcl | Azelastine Hcl | 63 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 15 |
| Linzess | Linaclotide | 62 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 19 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 59 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 11 |
| Fluconazole | Fluconazole | 58 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 22 |
| Spironolactone | Spironolactone | 57 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Levofloxacin | Levofloxacin | 55 | 49 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 12 |
| Baclofen | Baclofen | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 14 |
| Metformin Hcl Er | Metformin Hcl | 51 | 15 |
| Mupirocin | Mupirocin | 51 | 35 |
| Fenofibrate | Fenofibrate | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 12 |
| Valacyclovir | Valacyclovir Hcl | 45 | 26 |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 43 | 13 |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 11 |
| Nystatin | Nystatin | 40 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 28 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 16 |
| Metronidazole | Metronidazole | 35 | 30 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 31 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | 11 |
| Ketoconazole | Ketoconazole | 29 | 18 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Premarin | Estrogens, Conjugated | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | 11 |
| Cefdinir | Cefdinir | 25 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 25 | 17 |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 17 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | 14 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.53 · 14 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE 3, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, YUPELRI, ZTLido | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error